Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Annual report

9776.TEDINET S100OJXV
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
MetricValuePeriodScopeSource row
Revenue¥19.1bn2021-04-01 → 2022-03-31Cons.Net sales
Revenue¥17.5bn2020-04-01 → 2021-03-31Cons.Net sales
Revenue¥17.7bn2019-04-01 → 2020-03-31dCons.Net sales (5-year summary)
Revenue¥17.1bn2018-04-01 → 2019-03-31dCons.Net sales (5-year summary)
Revenue¥17.5bn2017-04-01 → 2018-03-31dCons.Net sales (5-year summary)
Operating income¥1.5bn2021-04-01 → 2022-03-31Cons.Operating income
Operating income¥1.1bn2020-04-01 → 2021-03-31Cons.Operating income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31Cons.Ordinary income
Ordinary income¥1.2bn2020-04-01 → 2021-03-31Cons.Ordinary income
Ordinary income¥983m2019-04-01 → 2020-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥813m2018-04-01 → 2019-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2017-04-01 → 2018-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥1.5bn2021-04-01 → 2022-03-31Cons.Income before income taxes
Profit before tax¥1.2bn2020-04-01 → 2021-03-31Cons.Income before income taxes
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥794m2020-04-01 → 2021-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥528m2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥523m2018-04-01 → 2019-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥685m2017-04-01 → 2018-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss
Net income¥794m2020-04-01 → 2021-03-31Cons.Profit loss
Total assets¥16.1bnat 2022-03-31Cons.Assets
Total assets¥14.5bnat 2021-03-31Cons.Assets
Total assets¥11.6bnat 2020-03-31dCons.Total assets (5-year summary)
Total assets¥10.7bnat 2019-03-31dCons.Total assets (5-year summary)
Total assets¥10.6bnat 2018-03-31dCons.Total assets (5-year summary)
Total liabilities¥5.8bnat 2022-03-31Cons.Liabilities
Total liabilities¥5.2bnat 2021-03-31Cons.Liabilities
Net assets / equity¥10.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥9.3bnat 2021-03-31Cons.Net assets
Net assets / equity¥8.5bnat 2020-03-31dCons.Net assets
Net assets / equity¥8.0bnat 2019-03-31dCons.Net assets (5-year summary)
Net assets / equity¥7.6bnat 2018-03-31dCons.Net assets (5-year summary)
Cash and deposits¥3.0bnat 2022-03-31Cons.Cash and deposits
Cash and deposits¥2.4bnat 2021-03-31Cons.Cash and deposits
Cash & equivalents¥3.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.4bnat 2021-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.7bnat 2020-03-31dCons.Cash and cash equivalents
Cash & equivalents¥4.4bnat 2019-03-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.0bnat 2018-03-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥1.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥838m2020-04-01 → 2021-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥1.3bn2019-04-01 → 2020-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥647m2018-04-01 → 2019-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.3bn2017-04-01 → 2018-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥831m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥3.1bn2020-04-01 → 2021-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.9bn2019-04-01 → 2020-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥80m2018-04-01 → 2019-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥293m2017-04-01 → 2018-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥113m2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities
Financing cash flow¥1.9bn2020-04-01 → 2021-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥52m2019-04-01 → 2020-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥146m2018-04-01 → 2019-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥95m2017-04-01 → 2018-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥231.852020-04-01 → 2021-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥154.32019-04-01 → 2020-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥152.422018-04-01 → 2019-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥197.032017-04-01 → 2018-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥3,016.24at 2022-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥2,708.63at 2021-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥2,472.23at 2020-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥2,331.49at 2019-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥2,194.08at 2018-03-31dCons.Net assets per share (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.9%at 2021-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.3%at 2020-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio74.7%at 2019-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio71.7%at 2018-03-31dCons.Equity to asset ratio (5-year summary)
ROE10.8%2021-04-01 → 2022-03-31Cons.Rate of return on equity (5-year summary)
ROE9.0%2020-04-01 → 2021-03-31Cons.Rate of return on equity (5-year summary)
ROE6.4%2019-04-01 → 2020-03-31dCons.Rate of return on equity (5-year summary)
ROE6.7%2018-04-01 → 2019-03-31dCons.Rate of return on equity (5-year summary)
ROE9.4%2017-04-01 → 2018-03-31dCons.Rate of return on equity (5-year summary)
Employees871at 2022-03-31Cons.Number of employees
Employees819at 2021-03-31Cons.Number of employees
Employees820at 2020-03-31dCons.Number of employees
Employees810at 2019-03-31dCons.Number of employees
Employees781at 2018-03-31dCons.Number of employees
Revenue¥17.7bn2021-04-01 → 2022-03-31StandaloneNet sales
Revenue¥16.4bn2020-04-01 → 2021-03-31StandaloneNet sales
Revenue¥16.5bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Revenue¥16.0bn2018-04-01 → 2019-03-31dStandaloneNet sales (5-year summary)
Revenue¥16.4bn2017-04-01 → 2018-03-31dStandaloneNet sales (5-year summary)
Operating income¥1.5bn2021-04-01 → 2022-03-31StandaloneOperating income
Operating income¥1.1bn2020-04-01 → 2021-03-31StandaloneOperating income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income¥1.2bn2020-04-01 → 2021-03-31StandaloneOrdinary income
Ordinary income¥944m2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥758m2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥998m2017-04-01 → 2018-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥1.5bn2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Profit before tax¥1.2bn2020-04-01 → 2021-03-31StandaloneIncome before income taxes
Net income¥1.0bn2021-04-01 → 2022-03-31StandaloneProfit loss
Net income¥791m2020-04-01 → 2021-03-31StandaloneProfit loss
Net income¥503m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income¥487m2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Net income¥650m2017-04-01 → 2018-03-31dStandaloneNet income loss (5-year summary)
Total assets¥14.4bnat 2022-03-31StandaloneAssets
Total assets¥13.7bnat 2021-03-31StandaloneAssets
Total assets¥10.7bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥9.9bnat 2019-03-31dStandaloneTotal assets (5-year summary)
Total assets¥9.9bnat 2018-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥4.6bnat 2022-03-31StandaloneLiabilities
Total liabilities¥4.6bnat 2021-03-31StandaloneLiabilities
Net assets / equity¥9.8bnat 2022-03-31StandaloneNet assets
Net assets / equity¥9.0bnat 2021-03-31StandaloneNet assets
Net assets / equity¥8.2bnat 2020-03-31dStandaloneNet assets
Net assets / equity¥7.8bnat 2019-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥7.4bnat 2018-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.0bnat 2022-03-31StandaloneCash and deposits
Cash and deposits¥2.0bnat 2021-03-31StandaloneCash and deposits
EPS (basic)¥300.672021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥231.12020-04-01 → 2021-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥147.042019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥141.842018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥186.82017-04-01 → 2018-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥232021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥232020-04-01 → 2021-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥102019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥102018-04-01 → 2019-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥112017-04-01 → 2018-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥2,934.15at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,633.22at 2021-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,398.25at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,264.33at 2019-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,137.75at 2018-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio68.1%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio66.0%at 2021-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio78.0%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio74.7%at 2018-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE10.9%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
ROE9.2%2020-04-01 → 2021-03-31StandaloneRate of return on equity (5-year summary)
ROE6.3%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
ROE6.4%2018-04-01 → 2019-03-31dStandaloneRate of return on equity (5-year summary)
ROE9.1%2017-04-01 → 2018-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued4,216,000at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2021-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued4,216,000at 2018-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees622at 2022-03-31StandaloneNumber of employees
Employees775at 2021-03-31StandaloneNumber of employees
Employees779at 2020-03-31dStandaloneNumber of employees
Employees774at 2019-03-31dStandaloneNumber of employees
Employees747at 2018-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 86
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentscapex2021-04-01 → 2022-03-31¥8m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsdepreciation2021-04-01 → 2022-03-31¥138,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2022-03-312 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2022-03-31¥103m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2022-03-31¥102m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2022-03-31¥906,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2022-03-31¥24m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2022-03-31¥71m
Clinical Testing Businessreportable segmentcapex2021-04-01 → 2022-03-31¥1.5bn
Clinical Testing Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥324m
Clinical Testing Businessreportable segmentemployeesat 2022-03-31528 pure
Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥7.4bn
Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥7.4bn
Clinical Testing Businessreportable segmentsegment assetsat 2022-03-31¥4.3bn
Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥1.0bn
Dispensing Pharmacy Businessreportable segmentcapex2021-04-01 → 2022-03-31¥149m
Dispensing Pharmacy Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥87m
Dispensing Pharmacy Businessreportable segmentemployeesat 2022-03-31297 pure
Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥10.6bn
Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥10.6bn
Dispensing Pharmacy Businessreportable segmentsegment assetsat 2022-03-31¥3.3bn
Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥879m
Medical Devices Sales And Maintenance Businessreportable segmentcapex2021-04-01 → 2022-03-31¥4m
Medical Devices Sales And Maintenance Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥8m
Medical Devices Sales And Maintenance Businessreportable segmentemployeesat 2022-03-3120 pure
Medical Devices Sales And Maintenance Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥2.2bn
Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥984m
Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2021-04-01 → 2022-03-31¥1.2bn
Medical Devices Sales And Maintenance Businessreportable segmentsegment assetsat 2022-03-31¥816m
Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥10m
—segment totalcapex2021-04-01 → 2022-03-31¥1.6bn
—segment totaldepreciation2021-04-01 → 2022-03-31¥420m
—segment totalrevenue2021-04-01 → 2022-03-31¥20.2bn
—segment totalrevenue external2021-04-01 → 2022-03-31¥19.0bn
—segment totalrevenue intersegment2021-04-01 → 2022-03-31¥1.2bn
—segment totalsegment assetsat 2022-03-31¥8.4bn
—segment totalsegment profit2021-04-01 → 2022-03-31¥1.9bn
Total Of Reportable Segments And Otherssegment totalcapex2021-04-01 → 2022-03-31¥1.6bn
Total Of Reportable Segments And Otherssegment totaldepreciation2021-04-01 → 2022-03-31¥420m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2022-03-31¥20.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2022-03-31¥19.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2022-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2022-03-31¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2022-03-31¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsdepreciation2020-04-01 → 2021-03-31¥213,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2020-04-01 → 2021-03-31¥87m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2020-04-01 → 2021-03-31¥86m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2020-04-01 → 2021-03-31¥721,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2021-03-31¥13m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2020-04-01 → 2021-03-31¥66m
Clinical Testing Businessreportable segmentcapex2020-04-01 → 2021-03-31¥312m
Clinical Testing Businessreportable segmentdepreciation2020-04-01 → 2021-03-31¥158m
Clinical Testing Businessreportable segmentrevenue2020-04-01 → 2021-03-31¥6.1bn
Clinical Testing Businessreportable segmentrevenue external2020-04-01 → 2021-03-31¥6.1bn
Clinical Testing Businessreportable segmentsegment assetsat 2021-03-31¥2.5bn
Clinical Testing Businessreportable segmentsegment profit2020-04-01 → 2021-03-31¥625m
Dispensing Pharmacy Businessreportable segmentcapex2020-04-01 → 2021-03-31¥111m
Dispensing Pharmacy Businessreportable segmentdepreciation2020-04-01 → 2021-03-31¥85m
Dispensing Pharmacy Businessreportable segmentrevenue2020-04-01 → 2021-03-31¥10.4bn
Dispensing Pharmacy Businessreportable segmentrevenue external2020-04-01 → 2021-03-31¥10.4bn
Dispensing Pharmacy Businessreportable segmentsegment assetsat 2021-03-31¥3.3bn
Dispensing Pharmacy Businessreportable segmentsegment profit2020-04-01 → 2021-03-31¥863m
Medical Devices Sales And Maintenance Businessreportable segmentcapex2020-04-01 → 2021-03-31¥5m
Medical Devices Sales And Maintenance Businessreportable segmentdepreciation2020-04-01 → 2021-03-31¥8m
Medical Devices Sales And Maintenance Businessreportable segmentrevenue2020-04-01 → 2021-03-31¥1.5bn
Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2020-04-01 → 2021-03-31¥836m
Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2020-04-01 → 2021-03-31¥652m
Medical Devices Sales And Maintenance Businessreportable segmentsegment assetsat 2021-03-31¥836m
Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2020-04-01 → 2021-03-31−¥1m
—segment totalcapex2020-04-01 → 2021-03-31¥429m
—segment totaldepreciation2020-04-01 → 2021-03-31¥251m
—segment totalrevenue2020-04-01 → 2021-03-31¥18.1bn
—segment totalrevenue external2020-04-01 → 2021-03-31¥17.4bn
—segment totalrevenue intersegment2020-04-01 → 2021-03-31¥652m
—segment totalsegment assetsat 2021-03-31¥6.7bn
—segment totalsegment profit2020-04-01 → 2021-03-31¥1.5bn
Total Of Reportable Segments And Otherssegment totalcapex2020-04-01 → 2021-03-31¥429m
Total Of Reportable Segments And Otherssegment totaldepreciation2020-04-01 → 2021-03-31¥251m
Total Of Reportable Segments And Otherssegment totalrevenue2020-04-01 → 2021-03-31¥18.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-04-01 → 2021-03-31¥17.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2020-04-01 → 2021-03-31¥653m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2021-03-31¥6.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2020-04-01 → 2021-03-31¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2022-03-312 pure
Clinical Testing Businessreportable segmentemployeesat 2022-03-31299 pure
Dispensing Pharmacy Businessreportable segmentemployeesat 2022-03-31297 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,457
ItemContextValueUnit
Current portion of long term loans payableCurrentYearInstant133692000JPY
Lease obligations clPrior1YearInstant23530000JPY
Lease obligations clCurrentYearInstant106041000JPY
Income taxes payablePrior1YearInstant249055000JPY
Income taxes payableCurrentYearInstant294056000JPY
Provision for bonusesPrior1YearInstant115210000JPY
Provision for bonusesCurrentYearInstant120975000JPY
Accounts payable otherPrior1YearInstant113662000JPY
Accounts payable otherCurrentYearInstant125075000JPY
Asset retirement obligations clPrior1YearInstant－JPY
Asset retirement obligations clCurrentYearInstant28000000JPY
Other clPrior1YearInstant176724000JPY
Other clCurrentYearInstant215389000JPY
Current liabilitiesPrior1YearInstant3105932000JPY
Current liabilitiesCurrentYearInstant3281795000JPY
Long term loans payablePrior1YearInstant1866013000JPY
Long term loans payableCurrentYearInstant1732321000JPY
Lease obligations nclPrior1YearInstant80203000JPY
Lease obligations nclCurrentYearInstant610978000JPY
Provision for directors retirement benefitsPrior1YearInstant57384000JPY
Provision for directors retirement benefitsCurrentYearInstant66870000JPY
Net defined benefit liabilityPrior1YearInstant14460000JPY
Net defined benefit liabilityCurrentYearInstant16107000JPY
Long term accounts payable otherPrior1YearInstant110440000JPY
Long term accounts payable otherCurrentYearInstant97363000JPY
Other nclPrior1YearInstant4652000JPY
Other nclCurrentYearInstant6053000JPY
Noncurrent liabilitiesPrior1YearInstant2133154000JPY
Noncurrent liabilitiesCurrentYearInstant2529694000JPY
LiabilitiesPrior1YearInstant5239086000JPY
LiabilitiesCurrentYearInstant5811490000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentYearInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentYearInstant1015270000JPY
Retained earningsPrior1YearInstant7848543000JPY
Retained earningsCurrentYearInstant8812690000JPY
Treasury stockPrior1YearInstant-633207000JPY
Treasury stockCurrentYearInstant-728236000JPY
Shareholders equityPrior1YearInstant9213955000JPY
Shareholders equityCurrentYearInstant10083073000JPY
Valuation difference on available for sale securitiesPrior1YearInstant58429000JPY
Valuation difference on available for sale securitiesCurrentYearInstant31227000JPY
Valuation and translation adjustmentsPrior1YearInstant58429000JPY
Valuation and translation adjustmentsCurrentYearInstant31227000JPY
Non controlling interestsPrior1YearInstant－JPY
Non controlling interestsCurrentYearInstant223659000JPY
Net assetsPrior1YearInstant9272384000JPY
Net assetsCurrentYearInstant10337959000JPY
Liabilities and net assetsPrior1YearInstant14511471000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2021-03-31pass rounding
balance sheet identityconsolidated 2022-03-31pass
balance sheet identitynon_consolidated 2021-03-31pass
balance sheet identitynon_consolidated 2022-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2020-03-31pass
statement vs summary · net assetsconsolidated 2021-03-31pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2020-03-31pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2020-04-01/2021-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2020-04-01/2021-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenueconsolidated 2020-04-01/2021-03-31pass
statement vs summary · revenueconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2020-04-01/2021-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · total assetsconsolidated 2021-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2021-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass